Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vero Cell-Derived H5N1 Vaccine in Healthy Japanese Adults
NCT01382329Phase 3Completed
- Sponsor
- Resilience Government Services
- Start
- Jun 2011
- Primary completion
- Aug 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of inactivated influenza vaccine, whole virion, vero cell-derived (4 arms), sponsored by Resilience Government Services. Primary endpoints: Number of subjects with antibody response to the vaccine strain, Number of subjects demonstrating seroconversion and 1 more. Started Jun 2011; status: completed.
02
Drugs
inactivated influenza vaccine, whole virion, vero cell-derived
Beyond the preview
Go deeper on NCT01382329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01382329.